Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

“…27 Tere are economic benefts of olanzapine. Four days of generic oral olanzapine at 10 mg/day, the dose used in this study and previous prophylactic studies, [7][8][9][10] is about $3.00, 28 which is signifcantly lower than the cost of 1 day of intravenous fosaprepitant at 150 mg (approximate wholesale acquisition cost: $257.00). 29 Te nausea and vomiting observed in the current study was presumably because of both the HEC and the concurrent radiotherapy.…”

“…8 For the 121 patients receiving the olanzapine regimen and the 120 patients receiving the aprepitant regimen, there were no signifcant diferences in CR rates in the acute, delayed, or overall periods. Te number of patients with no nausea (0, scale 0-10, visual analogue scale) was signifcantly higher in the delayed and overall periods for the patients who received the olanzapine regimen 8 . Te beneft of olanzapine for decreasing nausea has also been demonstrated in other phase 3 clinic trials.…”

“…1 Tere have been signifcant improvements in recent years in the control of chemotherapy-induced emesis with the use of the 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, 2,3 dexamethasone, 2,3 the neurokinin-1(NK-1) receptor antagonists, [4][5][6] and olanzapine, an antipsychotic that blocks multiple neurotransmitters in the central nervous system. [7][8][9] Chemotherapy-induced nausea, however, has not been as well controlled and remains a signifcant clinical problem. [8][9][10] Radiation-induced nausea and vomiting (RINV) also has a signifcant adverse efect on life qualit y.…”

“…[7][8][9] Chemotherapy-induced nausea, however, has not been as well controlled and remains a signifcant clinical problem. [8][9][10] Radiation-induced nausea and vomiting (RINV) also has a signifcant adverse efect on life qualit y. [11][12][13] Few reported clinical trials have provided efective prevention or treatment recommendations for RINV.…”

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

“…Five new trials were identified. [3][4][5][6][7] The study by Hoshi et al 5 provided additional data (Data Supplement) that support use of aprepitant for patients undergoing high-risk chemotherapy.…”